Cancer Physiology Department News

Dr. Bob Gillies

Moffitt and the Cancer Physiology Department Mourn the Loss of Former Chair Dr. Robert Gillies

The global research community lost a great leader, scientist and collaborator. Dr. Robert Gillies' vision and work over the past 14 years made an indelible mark on Moffitt Cancer Center's success and helped pave the future. Throughout his career, he was an incredible mentor to students, postdoctoral fellows and faculty. Read more

Alpha Particle Therapy clinical team members

Alpha-Particle Therapy Targeted to Metastatic Uveal Melanoma

A first-in-human clinical trial to test a new targeted alpha-particle therapy in patients with metastatic uveal melanoma was opened at Moffitt Cancer Center in July 2022. Development of this new peptide receptor radiotherapy (PRRT) began eight years ago in the Morse laboratory and a multidisciplinary team performed preclinical studies led by Dr. Morse (biological studies), Dr. Moros and Tichacek (medical physics), Dr. McLaughlin (peptide chemistry, now at West Virginia University), and Dr. Wadas (radiochemistry, now at University of Iowa). Pre-IND studies were performed in collaboration with Modulation Therapeutics Inc. The clinical team at Moffitt, pictured above, administered targeted alpha particle therapy to patients for the first time in August 2022 and are following tolerability, efficacy, pharmacokinetics and radiation dosimetry. They include from left, Rebecca Rogers (Nuclear Medicine tech), William Gibbons (Radiation Safety official), Ghassan El-Haddad, MD (Interventional Radiology and Nuclear Medicine), Ken Gage MD, PhD (Nuclear Medicine), Nikhil Khushalani MD (Chief, Medical Oncology), Christopher Tichacek PhD, (Medical Physicist in Radiation Oncology) and Mikalai Budzevich PhD, (manager of the SAIL core).

Moffitt Cancer Center sponsors the "Cancer Metabolism Showcase and Workshops," a postdoc and student-focused event featuring 20 oral presentations, 85 posters, and career development workshops from members of the academia, industry, publishing and NIH community. This event was co-organized by Dr. Gina DeNicola. DeNicola lab science was represented by Nathan (oral presentation), Chang Jiang (poster presentation), and Laura Torrente (poster presentation).

DeNicola Lab Postdoctoral Fellow Nathan Ward was promoted to Research Instructor.

DeNicola Lab Research Instructor Chang Jiang published her work using CRISPR screening to identify redox vulnerabilities for NRF2/KEAP1 mutant lung cancer cells in Redox Biology.

Praneeth Reddy Sudalagunta presented his research titled "Functional Genomic Landscape of Multiple Myeloma Informed by TCC-Avatar Data Identifies Novel Therapeutic Strategies" at 2022 ORIEN Scientific Retreat in St. Petersburg, Florida. (March 3, 2022)

Rafael Renatino Canevarolo was invited to participate as a speaker at the First Workshop on Molecular Biology promoted by the Graduate Program on Biosciences and Biotechnology Applied to Pharmacy, from the São Paulo State University (Brazil). Title of the presentation: "Clinical Evolution of Multiple Myeloma and its Association with Dynamic Epigenetic Profiles." (March 25, 2022)

Praneeth Reddy Sudalagunta participated in the Biologically Informed Models of Combination Therapies IDEAS Lab organized by IBM Research and the National Cancer Institute (NCI). (May 9, 2022)

Rafael Renatino Canevarolo, representing Praneeth Reddy Sudalagunta, made an oral presentation of the research titled "Functional Genomic Landscape in Multiple Myeloma Identifies Novel Therapeutic Strategies," at the 2022 Moffitt Scientific Symposium.

Rafael Renatino Canevarolo received an Oral Presentation Award in the area of Quantitative Science at 2022 Moffitt Scientific Symposium. (May 11, 2022)

Praneeth Reddy Sudalagunta was awarded Research Instructor designation. (July 1, 2022)